Dr. David Malkin is the  co-principal investigator of the Crazy 8 team studying a vaccine for childhood cancer predisposition syndromes.

Dr. Malkin received his medical degree from the University of Toronto in 1984 and completed his residency in pediatrics and pediatric hematology/oncology at The Hospital for Sick Children in Toronto. He completed postdoctoral research training in molecular genetics at Massachusetts General Hospital, Harvard University, where he discovered the link between germline mutations in the TP53 tumor suppressor gene and the Li-Fraumeni cancer susceptibility syndrome. Dr. Malkin returned to Canada to accept a faculty position at SickKids and University of Toronto in 1992.

Dr. Malkin is the Lead of the SickKids Precision Child Health initiative. He is co-Director of the SickKids Cancer Sequencing (KiCS) program which integrates and translates next generation sequencing into clinical care of children with cancer, and Director of the pan-Canadian multi-institutional PRecision Oncology For Young peopLE (PROFYLE) initiative which is establishing a pipeline to incorporate next generation sequencing into novel clinical trials (‘precision oncology’) for children and young adults with hard-to-treat cancers across Canada.

Dr. Malkin’s research program focuses on genetic and genomic mechanisms of childhood cancer susceptibility which he has explored particularly in the context of TP53 and Li-Fraumeni syndrome.